1. Home
  2. CRNX vs SUNC Comparison

CRNX vs SUNC Comparison

Compare CRNX & SUNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$41.08

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Logo SunocoCorp LLC

SUNC

SunocoCorp LLC

N/A

Current Price

$67.62

Market Cap

3.2B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
CRNX
SUNC
Founded
2008
2000
Country
United States
United States
Employees
N/A
8910
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
3.2B
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
CRNX
SUNC
Price
$41.08
$67.62
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
2
Target Price
$76.75
$61.00
AVG Volume (30 Days)
968.2K
433.5K
Earning Date
05-07-2026
05-05-2026
Dividend Yield
N/A
5.74%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,039,000.00
N/A
Revenue This Year
$720.10
$65.29
Revenue Next Year
$184.67
$0.84
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.83
$47.00
52 Week High
$57.99
$68.19

Technical Indicators

Market Signals
Indicator
CRNX
SUNC
Relative Strength Index (RSI) 60.96 63.79
Support Level $39.88 $58.79
Resistance Level $41.33 N/A
Average True Range (ATR) 1.52 1.43
MACD 0.27 0.39
Stochastic Oscillator 76.34 84.35

Price Performance

Historical Comparison
CRNX
SUNC

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

About SUNC SunocoCorp LLC

SunocoCorp LLC is a publicly traded limited liability company that owns a direct limited partner interest in Sunoco LP. It engages in the management and distribution of fuel products. It operates through the following segments: Fuel Distribution, Pipeline Systems, and Terminals and Refinery.

Share on Social Networks: